drugset
drugset / Trial / NCT05975554

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.

NCT05975554 ↗

Active not recruiting 30 enrolled Cambridge University Hospitals NHS Foundation Trust
RandomizedParallel-groupOpen-labelBasic science

Summary

The goal of this clinical trail is to compare the differences in carotid plaque Treg cells' gene signature for activation, proliferation, and suppressive function using scRNA-seq in patients treated with IL-2 compared to control.

Timeline

Start
2023-08-26
Primary completion
2025-02-01
Completion
2025-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic 1.5e+06 iu Subcutaneous

Indications

atherosclerosis transient ischemic attack